decemb
novel
pneumonia
caus
previous
unknown
pathogen
emerg
wuhan
citi
million
peopl
central
china
initi
case
link
exposur
seafood
market
januari
chines
author
report
confirm
case
mainland
china
includ
death
addit
confirm
case
identifi
hong
kong
macao
taiwan
import
case
identifi
thailand
japan
south
korea
unit
state
vietnam
singapor
nepal
franc
australia
canada
pathogen
soon
identifi
novel
coronaviru
close
relat
sever
acut
respiratori
syndrom
cov
sarscov
current
specif
treatment
new
viru
therefor
identifi
effect
antivir
agent
combat
diseas
urgent
need
effici
approach
drug
discoveri
test
whether
exist
antivir
drug
effect
treat
relat
viral
infect
belong
betacoronaviru
also
contain
sarscov
middl
east
respiratori
syndrom
cov
merscov
sever
drug
ribavirin
interferon
lopinavirritonavir
corticosteroid
use
patient
sar
mer
although
efficaci
drug
remain
studi
evalu
antivir
effici
five
fadapprov
drug
includ
ribavirin
penciclovir
nitazoxanid
nafamostat
chloroquin
two
wellknown
broadspectrum
antivir
drug
remdesivir
favipiravir
clinic
isol
vitro
standard
assay
carri
measur
effect
compound
cytotox
viru
yield
infect
rate
firstli
cytotox
candid
compound
vero
cell
determin
assay
vero
cell
infect
multipl
infect
moi
presenc
vari
concentr
test
drug
dmso
use
control
efficaci
evalu
quantif
viral
copi
number
cell
supernat
via
quantit
realtim
rtpcr
qrtpcr
confirm
visual
viru
nucleoprotein
np
express
immunofluoresc
microscopi
h
post
infect
pi
cytopath
effect
obviou
time
point
infect
among
seven
test
drug
high
concentr
three
nucleosid
analog
includ
ribavirin
halfmaxim
effect
concentr
halfcytotox
concentr
select
index
si
penciclovir
si
favipiravir
si
requir
reduc
viral
infect
fig
supplementari
inform
fig
howev
favipiravir
shown
effect
protect
mice
ebola
viru
challeng
although
valu
vero
cell
high
suggest
vivo
studi
recommend
evalu
antivir
nucleosid
nafamostat
potent
inhibitor
merscov
prevent
membran
fusion
inhibit
infect
si
nitazoxanid
commerci
antiprotozo
agent
antivir
potenti
broad
rang
virus
includ
human
anim
coronavirus
inhibit
lowmicromolar
concentr
si
vivo
evalu
drug
infect
recommend
notabl
two
compound
remdesivir
si
chloroquin
si
potent
block
viru
infect
lowmicromolar
concentr
show
high
si
fig
b
remdesivir
recent
recogn
promis
antivir
drug
wide
array
rna
virus
includ
infect
cultur
cell
mice
nonhuman
primat
nhp
model
current
clinic
develop
treatment
ebola
viru
remdesivir
adenosin
analogu
incorpor
nascent
viral
rna
chain
result
prematur
timeofaddit
assay
show
remdesivir
function
stage
post
viru
entri
fig
agreement
put
antivir
mechan
nucleotid
analogu
warren
et
al
show
nhp
model
intraven
administr
mgkg
dose
remdesivir
result
concomit
persist
level
activ
form
blood
confer
protect
ebola
viru
data
show
valu
remdesivir
vero
cell
suggest
work
concentr
like
achiev
nhp
preliminari
data
supplementari
inform
fig
show
remdesivir
also
inhibit
viru
infect
effici
human
cell
line
human
liver
cancer
cell
sensit
chloroquin
widelyus
antimalari
autoimmun
diseas
drug
recent
report
potenti
broadspectrum
antivir
chloroquin
known
block
viru
infect
increas
endosom
ph
requir
viruscel
fusion
well
interf
glycosyl
cellular
receptor
timeofaddit
assay
demonstr
chloroquin
function
entri
postentri
stage
infect
vero
cell
fig
besid
antivir
activ
chloroquin
immunemodul
activ
may
synergist
enhanc
antivir
effect
vivo
chloroquin
wide
distribut
whole
bodi
includ
lung
oral
administr
valu
chloroquin
vero
cell
clinic
achiev
demonstr
plasma
rheumatoid
arthriti
patient
receiv
mg
chloroquin
cheap
safe
drug
use
year
therefor
potenti
clinic
applic
find
reveal
remdesivir
chloroquin
highli
effect
control
infect
vitro
sinc
compound
use
human
patient
safeti
track
record
shown
effect
variou
ailment
suggest
assess
human
patient
suffer
novel
coronaviru
diseas
